

Jann N Sarkaria

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1191913/publications.pdf>

Version: 2024-02-01

172
papers

13,697
citations

50170

46
h-index

23472

111
g-index

174
all docs

174
docs citations

174
times ranked

19144
citing authors

#	ARTICLE	IF	CITATIONS
1	Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulinâ€”a novel tumor checkpoint controller targeting microtubules. <i>Neuro-Oncology</i> , 2022, 24, 384-395.	0.6	7
2	Matrix Hyaluronic Acid and Hypoxia Influence a CD133⁺ Subset of Patient-Derived Glioblastoma Cells. <i>Tissue Engineering - Part A</i> , 2022, 28, 330-340.	1.6	3
3	Multimodal platform for assessing drug distribution and response in clinical trials. <i>Neuro-Oncology</i> , 2022, 24, 64-77.	0.6	4
4	massNet: integrated processing and classification of spatially resolved mass spectrometry data using deep learning for rapid tumor delineation. <i>Bioinformatics</i> , 2022, 38, 2015-2021.	1.8	13
5	The influence of the bloodâ€”brain barrier in the treatment of brain tumours. <i>Journal of Internal Medicine</i> , 2022, 292, 3-30.	2.7	23
6	RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma. <i>Neuro-Oncology</i> , 2022, 24, 1261-1272.	0.6	6
7	Central Nervous System Delivery of the Catalytic Subunit of DNA-Dependent Protein Kinase Inhibitor Peposertib as Radiosensitizer for Brain Metastases. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2022, 381, 217-228.	1.3	7
8	Factors Influencing Luciferase-Based Bioluminescent Imaging in Preclinical Models of Brain Tumor. <i>Drug Metabolism and Disposition</i> , 2022, 50, 277-286.	1.7	6
9	Selective Vulnerability of Senescent Glioblastoma Cells to BCL-XL Inhibition. <i>Molecular Cancer Research</i> , 2022, 20, 938-948.	1.5	22
10	Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy. <i>Science Advances</i> , 2022, 8, eabl6339.	4.7	6
11	IL-13R α 2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma. <i>Pharmaceutics</i> , 2022, 14, 922.	2.0	4
12	Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	6
13	Characterization of Transgenic NSG-SGM3 Mouse Model of Precision Radiation-Induced Chronic Hyposalivation. <i>Radiation Research</i> , 2022, 198, .	0.7	2
14	Phage Particles of Controlled Length and Genome for <i>In Vivo</i> Targeted Glioblastoma Imaging and Therapeutic Delivery. <i>ACS Nano</i> , 2022, 16, 11676-11691.	7.3	19
15	Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining. <i>Cancer Research</i> , 2021, 81, 3333-3346.	0.4	16
16	<i>In Vivo</i> Efficacy of Tesevatinib in <i>EGFR</i> -Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1009-1018.	1.9	11
17	EGFRvIII tumorigenicity requires PDGFRA co-signaling and reveals therapeutic vulnerabilities in glioblastoma. <i>Oncogene</i> , 2021, 40, 2682-2696.	2.6	9
18	Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma. <i>Molecular Medicine</i> , 2021, 27, 28.	1.9	8

#	ARTICLE	IF	CITATIONS
19	Quantitative Analysis of Tyrosine Phosphorylation from FFPE Tissues Reveals Patient-Specific Signaling Networks. <i>Cancer Research</i> , 2021, 81, 3930-3941.	0.4	16
20	Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma. <i>Neuro-Oncology</i> , 2021, 23, 2042-2053.	0.6	37
21	Efflux Limits Tumor Drug Delivery Despite Disrupted BBB. <i>Trends in Pharmacological Sciences</i> , 2021, 42, 426-428.	4.0	9
22	Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells. <i>Communications Biology</i> , 2021, 4, 718.	2.0	14
23	Experimental Design of Preclinical Experiments: Number of PDX Lines versus Subsampling within PDX Lines. <i>Neuro-Oncology</i> , 2021, 23, 2066-2075.	0.6	1
24	Initial Results of a Phase 2 Trial of 18F-DOPA PET-Guided Dose-Escalated Radiation Therapy for Glioblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1383-1395.	0.4	31
25	TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas. <i>Clinical Cancer Research</i> , 2021, 27, 5669-5680.	3.2	4
26	Preclinical Risk Evaluation of Normal Tissue Injury With Novel Radiosensitizers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, e54-e62.	0.4	7
27	Changes in the vasculature of human brain tumors: Implications for treatment. <i>Neuro-Oncology</i> , 2021, 23, 1995-1997.	0.6	2
28	Peak learning of mass spectrometry imaging data using artificial neural networks. <i>Nature Communications</i> , 2021, 12, 5544.	5.8	43
29	Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 379, 343-357.	1.3	7
30	Methods for intratumoral microdialysis probe targeting and validation in murine brain tumor models. <i>Journal of Neuroscience Methods</i> , 2021, 363, 109321.	1.3	3
31	Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1131-1139.	0.4	5
32	Protein kinase C δ 1 and SRC signaling define reciprocally related subgroups of glioblastoma with distinct therapeutic vulnerabilities. <i>Cell Reports</i> , 2021, 37, 110054.	2.9	6
33	The novel BET inhibitor UM-002 reduces glioblastoma cell proliferation and invasion. <i>Scientific Reports</i> , 2021, 11, 23370.	1.6	14
34	Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clones. <i>Neuro-Oncology</i> , 2020, 22, 70-83.	0.6	12
35	Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor. <i>Scientific Reports</i> , 2020, 10, 15195.	1.6	19
36	ST3GAL1 is a target of the SOX2-GLI1 transcriptional complex and promotes melanoma metastasis through AXL. <i>Nature Communications</i> , 2020, 11, 5865.	5.8	54

#	ARTICLE	IF	CITATIONS
37	Crosstalk between microglia and patient-derived glioblastoma cells inhibit invasion in a three-dimensional gelatin hydrogel model. <i>Journal of Neuroinflammation</i> , 2020, 17, 346.	3.1	21
38	Targeting the RhoGEF Î²PIX/COOL-1 in Glioblastoma: Proof of Concept Studies. <i>Cancers</i> , 2020, 12, 3531.	1.7	4
39	Purine metabolism regulates DNA repair and therapy resistance in glioblastoma. <i>Nature Communications</i> , 2020, 11, 3811.	5.8	103
40	Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2163-2174.	1.9	17
41	Quantifying Glioblastoma Drug Response Dynamics Incorporating Treatment Sensitivity and Blood Brain Barrier Penetrance From Experimental Data. <i>Frontiers in Physiology</i> , 2020, 11, 830.	1.3	8
42	Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors. <i>Pharmaceutics</i> , 2020, 12, 1205.	2.0	31
43	Semaphorin 3A mediated brain tumor stem cell proliferation and invasion in EGFRviii mutant gliomas. <i>BMC Cancer</i> , 2020, 20, 1213.	1.1	17
44	Brain metastases-derived extracellular vesicles induce binding and aggregation of low-density lipoprotein. <i>Journal of Nanobiotechnology</i> , 2020, 18, 162.	4.2	45
45	Radiation Induced Metabolic Alterations Associate With Tumor Aggressiveness and Poor Outcome in Glioblastoma. <i>Frontiers in Oncology</i> , 2020, 10, 535.	1.3	22
46	Enhancing Brain Retention of a KIF11 Inhibitor Significantly Improves its Efficacy in a Mouse Model of Glioblastoma. <i>Scientific Reports</i> , 2020, 10, 6524.	1.6	20
47	Comments on: "Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity". <i>Neuro-Oncology</i> , 2020, 22, 1404-1405.	0.6	0
48	Localized Metabolomic Gradients in Patient-Derived Xenograft Models of Glioblastoma. <i>Cancer Research</i> , 2020, 80, 1258-1267.	0.4	67
49	Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 1094-1104.	3.2	124
50	Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma. <i>PLoS ONE</i> , 2020, 15, e0230492.	1.1	10
51	Title is missing!. , 2020, 15, e0230492.		0
52	Title is missing!. , 2020, 15, e0230492.		0
53	Title is missing!. , 2020, 15, e0230492.		0
54	Title is missing!. , 2020, 15, e0230492.		0

#	ARTICLE	IF	CITATIONS
55	Hyaluronic acid-functionalized gelatin hydrogels reveal extracellular matrix signals temper the efficacy of erlotinib against patient-derived glioblastoma specimens. <i>Biomaterials</i> , 2019, 219, 119371.	5.7	34
56	Molecular profiling of long-term IDH-wildtype glioblastoma survivors. <i>Neuro-Oncology</i> , 2019, 21, 1458-1469.	0.6	47
57	Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 1529-1539.	0.6	21
58	The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. <i>Neuro-Oncology</i> , 2019, 21, 1498-1508.	0.6	49
59	Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors. <i>Cancer Research</i> , 2019, 79, 4331-4338.	0.4	44
60	Brain Distributional Kinetics of a Novel MDM2 Inhibitor SAR405838: Implications for Use in Brain Tumor Therapy. <i>Drug Metabolism and Disposition</i> , 2019, 47, 1403-1414.	1.7	13
61	Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells. <i>Molecular Medicine</i> , 2019, 25, 49.	1.9	27
62	Estrogen-related receptor β activation and isoform shifting by cdc2-like kinase inhibition restricts migration and intracranial tumor growth in glioblastoma. <i>FASEB Journal</i> , 2019, 33, 13476-13491.	0.2	19
63	Brain Distribution of a Panel of Epidermal Growth Factor Receptor Inhibitors Using Cassette Dosing in Wild-Type and <i>Abcb1/Abcg2</i> -Deficient Mice. <i>Drug Metabolism and Disposition</i> , 2019, 47, 393-404.	1.7	38
64	Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 1141-1149.	0.6	17
65	Fluorescent reporter assays provide direct, accurate, quantitative measurements of MGMT status in human cells. <i>PLoS ONE</i> , 2019, 14, e0208341.	1.1	15
66	Pathogenic Germ Line Variants in a Patient With Severe Toxicity From Breast Radiotherapy. <i>Clinical Breast Cancer</i> , 2019, 19, e400-e405.	1.1	1
67	Automatic 3D Nonlinear Registration of Mass Spectrometry Imaging and Magnetic Resonance Imaging Data. <i>Analytical Chemistry</i> , 2019, 91, 6206-6216.	3.2	45
68	Imaging and Dosimetry Study of Inter-fraction Setup Error in a Murine Xenograft Flank Tumor Radiation Model. <i>Radiation Research</i> , 2019, 193, 161.	0.7	4
69	Environmental Dynamics Underlying Responsive Extreme Survivors (ENDURES) of Glioblastoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 655-661.	0.6	3
70	Editorial: Targeted Therapies for Glioblastoma: A Critical Appraisal. <i>Frontiers in Oncology</i> , 2019, 9, 1216.	1.3	9
71	Quantifying the setup uncertainty of a stereotactic murine micro-image guided radiation therapy system. <i>British Journal of Radiology</i> , 2019, 92, 20180487.	1.0	9
72	Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 368, 446-461.	1.3	15

#	ARTICLE	IF	CITATIONS
73	Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas. <i>Clinical Cancer Research</i> , 2019, 25, 747-759.	3.2	35
74	Molecular and Structural Traits of Insulin Receptor Substrate 1/LC3 Nuclear Structures and Their Role in Autophagy Control and Tumor Cell Survival. <i>Molecular and Cellular Biology</i> , 2018, 38, .	1.1	5
75	Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. <i>Lancet Oncology</i> , The, 2018, 19, e240-e251.	5.1	108
76	Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. <i>Neuro-Oncology</i> , 2018, 20, 546-556.	0.6	93
77	Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases. <i>Drug Metabolism and Disposition</i> , 2018, 46, 658-666.	1.7	24
78	Pharmacokinetic Assessment of Cooperative Efflux of the Multitargeted Kinase Inhibitor Ponatinib Across the Blood-Brain Barrier. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 365, 249-261.	1.3	30
79	Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572. <i>Cancer</i> , 2018, 124, 1455-1463.	2.0	41
80	Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. <i>Neuro-Oncology</i> , 2018, 20, 184-191.	0.6	443
81	RDNA-04. POTENTIAL MECHANISM OF TEMOZOLOMIDE-MEDIATED RADIO-SENSITIZATION IN MGMT HYPERMETHYLATED GLIOBLASTOMA CELLS. <i>Neuro-Oncology</i> , 2018, 20, vi222-vi222.	0.6	0
82	RTHP-02. IMPACT OF 18F-DOPA PET ON RADIOTHERAPY TARGET VOLUMES FOR NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA PATIENTS; PRELIMINARY RESULTS OF A PHASE II DOSE-ESCALATION TRIAL. <i>Neuro-Oncology</i> , 2018, 20, vi225-vi225.	0.6	1
83	TMOD-11. IMAGING BASED INVASION METRIC PREDICTIVE OF RESPONSE TO ABT414 IN ORTHOTOPIC EGFRviii AMPLIFIED PATIENT DERIVED XENOGRAFTS. <i>Neuro-Oncology</i> , 2018, 20, vi270-vi271.	0.6	0
84	RDNA-06. A NOVEL ROLE OF SGEF IN MEDIATING GBM CELL SURVIVAL BY MODULATING THE DNA DAMAGE REPAIR MECHANISM. <i>Neuro-Oncology</i> , 2018, 20, vi222-vi223.	0.6	0
85	GENE-20. A NOVEL K-M ENHANCER REGULATES TEMOZOLOMIDE RESISTANCE AND TUMOR GROWTH IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi107-vi107.	0.6	0
86	TMIC-36. LOCAL TISSUE BIOMARKERS OF RESPONSE TO THERAPY FOR GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi264-vi264.	0.6	0
87	DDIS-25. TARGETING GLIOBLASTOMA HETEROGENEITY WITH miR-34a. <i>Neuro-Oncology</i> , 2018, 20, vi74-vi74.	0.6	0
88	TMOD-18. THE PATIENT DERIVED XENOGRAFT NATIONAL RESOURCE: A COMPREHENSIVE COLLECTION OF HIGH-GRADE GLIOMA MODELS FOR PRE-CLINICAL AND TRANSLATIONAL STUDIES. <i>Neuro-Oncology</i> , 2018, 20, vi272-vi272.	0.6	0
89	DDIS-01. THE ANTIBODY-DRUG CONJUGATE ABT-414 DEMONSTRATES SINGLE-AGENT ANTI-CANCER ACTIVITY ACROSS A PANEL OF GBM PATIENT-DERIVED XENOGRAFTS. <i>Neuro-Oncology</i> , 2018, 20, vi69-vi69.	0.6	4
90	CADD-57. THE EFFICACY OF THERAPY WITH ABT-414, AN EGFR-TARGETING ADC, IS POTENTIALLY ALTERED BY HETEROZYGOUS DELETION OF THE ENDOCYTIC TRAFFICKING REGULATOR RBSN. <i>Neuro-Oncology</i> , 2018, 20, vi283-vi284.	0.6	0

#	ARTICLE	IF	CITATIONS
91	TMOD-07. LOCALIZATION OF ERLONIB RELATIVE TO MRI-BASED TUMOR EXTENT IN PDX GLIOBLASTOMA MODEL: TOWARDS A MATHEMATICAL MODEL FOR THE INTERFACE BETWEEN MRI AND DRUG DISTRIBUTION. <i>Neuro-Oncology</i> , 2018, 20, vi269-vi270.	0.6	1
92	Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma. <i>Nature Communications</i> , 2018, 9, 4904.	5.8	62
93	DRES-17. ACTIVATION OF FGF SIGNALING PATHWAY CONFERS RESISTANCE TO EGFR INHIBITION IN GBM. <i>Neuro-Oncology</i> , 2018, 20, vi79-vi79.	0.6	0
94	ACTR-12. PRELIMINARY SAFETY AND EFFICACY OF A PHASE II TRIAL OF 18F-DOPA PET-GUIDED, DOSE-ESCALATED RADIOTHERAPY IN THE TREATMENT OF GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi13-vi13.	0.6	2
95	Drug and disease signature integration identifies synergistic combinations in glioblastoma. <i>Nature Communications</i> , 2018, 9, 5315.	5.8	78
96	IGFBP6 controls the expansion of chemoresistant glioblastoma through paracrine IGF2/IGF-1R signaling. <i>Cell Communication and Signaling</i> , 2018, 16, 61.	2.7	20
97	ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2462-2472.	1.9	59
98	Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1123-1132.	3.0	83
99	A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. <i>Nature Communications</i> , 2018, 9, 2949.	5.8	183
100	Influence of Hyaluronic Acid Transitions in Tumor Microenvironment on Glioblastoma Malignancy and Invasive Behavior. <i>Frontiers in Materials</i> , 2018, 5, .	1.2	74
101	H3.3K27M mutant proteins reprogram epigenome by sequestering the PRC2 complex to poised enhancers. <i>ELife</i> , 2018, 7, .	2.8	72
102	Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine. <i>Pharmaceutical Research</i> , 2018, 35, 177.	1.7	53
103	Distinctive epigenomes characterize glioma stem cells and their response to differentiation cues. <i>Genome Biology</i> , 2018, 19, 43.	3.8	81
104	Hypoxia-inducible factor 2Î±: a novel target in gliomas. <i>Future Medicinal Chemistry</i> , 2018, 10, 2227-2236.	1.1	28
105	A PDGFRÎ±-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine. <i>Nature Communications</i> , 2018, 9, 3116.	5.8	30
106	Presence of stromal cells in a bioengineered tumor microenvironment alters glioblastoma migration and response to STAT3 inhibition. <i>PLoS ONE</i> , 2018, 13, e0194183.	1.1	31
107	PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity. <i>Frontiers in Oncology</i> , 2018, 8, 670.	1.3	60
108	Immunovirotherapy with measles virus strains in combination with antiâ€œPD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. <i>Neuro-Oncology</i> , 2017, 19, now179.	0.6	85

#	ARTICLE	IF	CITATIONS
109	Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist. <i>Journal of Neurosurgery</i> , 2017, 126, 446-459.	0.9	39
110	Sulforaphane suppresses the growth of glioblastoma cells, glioblastoma stem cell-like spheroids, and tumor xenografts through multiple cell signaling pathways. <i>Journal of Neurosurgery</i> , 2017, 127, 1219-1230.	0.9	29
111	EGFR Signals through a DOCK180-MLK3 Axis to Drive Glioblastoma Cell Invasion. <i>Molecular Cancer Research</i> , 2017, 15, 1085-1095.	1.5	26
112	Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?. <i>Pharmacological Research</i> , 2017, 123, 10-25.	3.1	31
113	Characterization of relative biological effectiveness for conventional radiation therapy: a comparison of clinical 6 MV X-rays and ¹³⁷ Cs. <i>Journal of Radiation Research</i> , 2017, 58, 608-613.	0.8	23
114	A TNF- α -JNK- α -Axl- α -ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma. <i>Nature Neuroscience</i> , 2017, 20, 1074-1084.	7.1	82
115	Myosin-1E interacts with FAK proline-rich region 1 to induce fibronectin-type matrix. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 3933-3938.	3.3	18
116	Inhibiting DNA-PKCS radiosensitizes human osteosarcoma cells. <i>Biochemical and Biophysical Research Communications</i> , 2017, 486, 307-313.	1.0	29
117	Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 363, 136-147.	1.3	25
118	Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2735-2746.	1.9	58
119	Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival. <i>Clinical Cancer Research</i> , 2017, 23, 7059-7071.	3.2	26
120	CD90 Expression Controls Migration and Predicts Dasatinib Response in Glioblastoma. <i>Clinical Cancer Research</i> , 2017, 23, 7360-7374.	3.2	45
121	Extracellular Hyaluronic Acid Influences the Efficacy of EGFR Tyrosine Kinase Inhibitors in a Biomaterial Model of Glioblastoma. <i>Advanced Healthcare Materials</i> , 2017, 6, 1700529.	3.9	41
122	Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma. <i>Cancer Cell</i> , 2017, 32, 856-868.e5.	7.7	121
123	DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme. <i>Cancer Research</i> , 2017, 77, 198-206.	0.4	96
124	Radiogenomics to characterize regional genetic heterogeneity in glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, 128-137.	0.6	170
125	Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells. <i>Oncotarget</i> , 2017, 8, 16605-16620.	0.8	30
126	Real-Time Methylation-Specific Polymerase Chain Reaction for MGMT Promoter Methylation Clinical Testing in Glioblastoma. <i>American Journal of Clinical Pathology</i> , 2017, 148, 296-307.	0.4	5

#	ARTICLE	IF	CITATIONS
127	Investigating Dependencies of Relative Biological Effectiveness for Proton Therapy in Cancer Cells. <i>International Journal of Particle Therapy</i> , 2017, 4, 12-22.	0.9	28
128	Challenges in the Delivery of Therapies to Melanoma Brain Metastases. <i>Current Pharmacology Reports</i> , 2016, 2, 309-325.	1.5	18
129	Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1332-1343.	1.9	14
130	Network Modeling Identifies Patient-specific Pathways in Glioblastoma. <i>Scientific Reports</i> , 2016, 6, 28668.	1.6	25
131	SGEF Is Regulated via TWEAK/Fn14/NF- κ B Signaling and Promotes Survival by Modulation of the DNA Repair Response to Temozolomide. <i>Molecular Cancer Research</i> , 2016, 14, 302-312.	1.5	17
132	InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma. <i>Clinical Cancer Research</i> , 2016, 22, 1767-1776.	3.2	58
133	Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins. <i>Cell Reports</i> , 2016, 14, 2587-2598.	2.9	58
134	Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 356, 251-259.	1.3	18
135	Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 27-36.	0.6	210
136	ATPS-61NEW SMALL MOLECULES THAT KILL HYPOXICALLY TRANSFORMED GLIOMA STEM-LIKE CELLS. <i>Neuro-Oncology</i> , 2015, 17, v31.4-v31.	0.6	0
137	Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme. <i>Frontiers in Neuroscience</i> , 2015, 9, 218.	1.4	96
138	Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses. <i>PLoS ONE</i> , 2015, 10, e0125565.	1.1	22
139	Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition. <i>Oncotarget</i> , 2015, 6, 11751-11767.	0.8	9
140	A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. <i>Neuro-Oncology</i> , 2015, 17, 1261-1269.	0.6	126
141	MARQUIS: A multiplex method for absolute quantification of peptides and posttranslational modifications. <i>Nature Communications</i> , 2015, 6, 5924.	5.8	39
142	Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1210-9.	0.6	26
143	Dasatinib in recurrent glioblastoma: failure as a teacher. <i>Neuro-Oncology</i> , 2015, 17, 910-911.	0.6	27
144	Src family kinases differentially influence glioma growth and motility. <i>Molecular Oncology</i> , 2015, 9, 1783-1798.	2.1	52

#	ARTICLE	IF	CITATIONS
145	Convertible MRI contrast: Sensing the delivery and release of anti-glioma nano-drugs. <i>Scientific Reports</i> , 2015, 5, 9874.	1.6	37
146	The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 8326-8331.	3.3	186
147	The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma. <i>Clinical Cancer Research</i> , 2015, 21, 1916-1924.	3.2	86
148	Radiation Therapy Oncology Group 9802: Controversy or Consensus in the Treatment of Newly Diagnosed Low-Grade Glioma?. <i>Seminars in Radiation Oncology</i> , 2015, 25, 197-202.	1.0	19
149	Efflux Transporters at the Blood-Brain Barrier Limit Delivery and Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib (PD-0332991) in an Orthotopic Brain Tumor Model. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 355, 264-271.	1.3	84
150	Hirsutinolide Series Inhibit Stat3 Activity, Alter GCN1, MAP1B, Hsp105, G6PD, Vimentin, TrxR1, and Importin β -2 Expression, and Induce Antitumor Effects against Human Glioma. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 7734-7748.	2.9	22
151	Delineation of MGMT-Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. <i>Journal of the National Cancer Institute</i> , 2015, 108, djv369.	3.0	102
152	Multi-Parametric MRI and Texture Analysis to Visualize Spatial Histologic Heterogeneity and Tumor Extent in Glioblastoma. <i>PLoS ONE</i> , 2015, 10, e0141506.	1.1	104
153	Peptide Carrier-Mediated Non-Covalent Delivery of Unmodified Cisplatin, Methotrexate and Other Agents via Intravenous Route to the Brain. <i>PLoS ONE</i> , 2014, 9, e97655.	1.1	30
154	BET bromodomain proteins are required for glioblastoma cell proliferation. <i>Epigenetics</i> , 2014, 9, 611-620.	1.3	123
155	PM-19 * DEVELOPMENT OF A PANEL OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS FROM BRAIN METASTASES. <i>Neuro-Oncology</i> , 2014, 16, v173-v173.	0.6	2
156	Factors Influencing the CNS Distribution of a Novel MEK-1/2 Inhibitor: Implications for Combination Therapy for Melanoma Brain Metastases. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1292-1300.	1.7	89
157	Design and characterization of an economical ¹⁹² Ir hemi-brain small animal irradiator. <i>International Journal of Radiation Biology</i> , 2014, 90, 936-942.	1.0	3
158	A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas. <i>Oncotarget</i> , 2014, 5, 4026-4039.	0.8	62
159	Lung stereotactic body radiotherapy using a coplanar versus a non-coplanar beam technique: a comparison of clinical outcomes. <i>Journal of Radiosurgery and SBRT</i> , 2013, 2, 225-233.	0.2	1
160	Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts. <i>Clinical Cancer Research</i> , 2012, 18, 4070-4079.	3.2	127
161	Establishment, Maintenance, and In Vitro and In Vivo Applications of Primary Human Glioblastoma Multiforme (GBM) Xenograft Models for Translational Biology Studies and Drug Discovery. <i>Current Protocols in Pharmacology</i> , 2011, 52, Unit 14.16.	4.0	185
162	Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance. <i>Journal of Neuro-Oncology</i> , 2010, 100, 177-186.	1.4	48

#	ARTICLE	IF	CITATIONS
163	Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1. <i>Cancer Cell</i> , 2010, 17, 98-110.	7.7	6,138
164	Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. <i>Neuro-Oncology</i> , 2009, 11, 281-291.	0.6	289
165	Radiosensitizing Effects of Temozolomide Observed in vivo only in a Subset of O6-Methylguanine-DNA Methyltransferase Methylated Glioblastoma Multiforme Xenografts. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 212-219.	0.4	77
166	Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma. <i>Clinical Cancer Research</i> , 2008, 14, 2900-2908.	3.2	319
167	Overview of cancer molecular radiobiology. <i>Cancer Treatment and Research</i> , 2008, 139, 117-33.	0.2	5
168	Phase I Trial of Sirolimus Combined with Radiation and Cisplatin in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, 751-757.	0.5	47
169	Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy. <i>Journal of Neurosurgery</i> , 2007, 107, 610-616.	0.9	74
170	Use of an Orthotopic Xenograft Model for Assessing the Effect of Epidermal Growth Factor Receptor Amplification on Glioblastoma Radiation Response. <i>Clinical Cancer Research</i> , 2006, 12, 2264-2271.	3.2	242
171	Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. <i>Neuro-Oncology</i> , 2005, 7, 164-176.	0.6	296
172	Identifying Inhibitors of ATM and ATR Kinase Activities. , 2003, 85, 49-56.		19